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A b s t r a c t
Free, unbound and therefore biologically available ionised magnesium (IMg) plays vital 
roles in a variety of physiological and biochemical processes. This includes the proper 
functioning of many enzyme systems and the regulation of transmembrane movements 
of cations. The cardiovascular system is highly dependent on IMg, and numerous 
studies indicate that decreases in IMg concentrations are associated with a number of 
cardiovascular disease states.
Coronary heart disease with myocardial infarction is a leading cause of death, with 
patient survival enhanced by quick and accurate diagnosis. Quick diagnosis by the 
physician and prompt therapeutic intervention (i.e. thrombolytics or invasive surgery) 
can minimise damage to the heart muscle. However, in a large group of patients an 
accurate diagnosis of acute myocardial infarction (AMI) cannot be made rapidly and is 
only possible after biochemical testing.
The aim of this study was to determine serum IMg, total magnesium (TMg) and 
Creatine Kinase-MB (CK-MB) concentrations in patients with AMI and in other 
patients admitted to hospital on account of chest pain in which a diagnosis of AMI was 
ruled out. The study was undertaken to evaluate any trends in IMg concentrations 
associated with AMI, and to determine if IMg concentrations could be used as a 
diagnostic tool for AMI. Blood samples were taken from volunteers (n = 72) with 
suspected AMI on admission to hospital and at approximately 6 hour intervals, for up to 
66 hours, after the onset of chest pain. A control group of non-AMI volunteers (n = 90) 
(age and sex matched) was also monitored within the same time intervals.
Abstract Xll
Measurement of serum TMg did not serve as a reliable indicator of magnesium status in 
patients with AMI. Total magnesium concentrations remained constant (.P = 0.996) 
throughout the monitoring period of the AMI group, despite a drop in IMg over the 
same period. Statistically significant differences (P <0.001) in IMg concentrations were 
found between the AMI and non-AMI groups. At the 1 8 - 2 4  hour time interval the 
IMg concentration of the AMI group decreased significantly (P <0.001) by 7.0%, 
returning to pre-infarction levels between 30 -  42 hours. The serum IMg concentrations 
were unchanged (P = 0.276) in the non-AMI group.
Results from this study support the conclusion that it may be clinically useful to monitor 
IMg in patients with AMI. From the data available, however, the low sensitivity (61%) 
and specificity (71%) of IMg in predicting AMI reduced its use as a clinical diagnostic 
tool for the detection of myocardial injury.
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C h a p t e r  1 -
T h e  r o l e  o f  io n is e d  m a g n e s iu m  in
CARDIOVASCULAR FUNCTION AND
PATHOLOGY
1.1 Introduction -  General overview of magnesium function
Magnesium is an important biological element and an essential requirement for all 
living things. It is present in all cells and is the fourth most abundant metal element in 
the body and the second most abundant intracellular cation, potassium being the most 
abundant (118). A common, essential dietary element and electrolyte, magnesium plays 
major roles in health and disease. Magnesium is gaining increasing attention following 
experimental and clinical studies on its biological roles and pharmacological influences. 
Free, i.e. unbound or ionised magnesium (IMg), is the biologically active form and 
plays a major role in numerous cellular processes, such as in the regulation of 
transmembrane ionic fluxes, excitation-contraction coupling, and energy metabolism.
Table 1.1 lists some of the physiological functions of IMg. In the human body, IMg is 
an essential cofactor for over 320 enzymes. Ionised magnesium is essential for many 
physiological processes by serving as a co-factor predominantly involved in the transfer, 
storage and utilisation of energy (15). It plays important roles in enzymatic reactions in 
two general ways. Complexes formed from the binding of magnesium and substrate 
facilitate enzyme interaction with the substrate. Alternatively, magnesium ions bind 
directly to the enzyme, altering its structure and/or serving a catalytic role. 
For example, by activating phosphate groups and reactions that involve adenosine 
triphosphate (ATP), the cytoplasmic and mitochondrial level of IMg serves to regulate 
the processes of glycolysis and Krebs cycle (9, 135).
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Table 1.1




Function Membrane Function Calcium Antagonist
7 Glycolytic Enzymes Proteins
2+
Gating of Ca channels Muscle contraction/relaxation
5 Krebs Cycle Polyribosomes Transmembrane flux of ions Action potential conduction in
Enzymes Nucleic acids Adenylate cyclase system nodal tissue
Membrane ATPases Mitochondria
Kinases-creatine kinase
Reproduced from reference (15).
Because of its numerous biochemical cellular activities, IMg plays an important role in 
control of cardiac excitability, vasomotor tone, muscular contraction, blood pressure 
and peripheral blood flow. Recent work has suggested that IMg can affect myocardial 
contractility and excitability by a number of cellular pathways (115). The regulation of 
transmembrane ion fluxes constitutes a most important aspect of the part played by IMg 
in cardiac function. Nerve and muscle cells of the heart and the vasculature require 
IMg, together with potassium and calcium, to conduct electrical impulses and/or to 
contract. Ionised magnesium serves to regulate potassium concentrations by 
influencing the function of sodium/potassium adenosine triphosphatase (Na+/K+- 
ATPase) pumps, voltage-gated potassium channels and acetylcholine-gated cation 
channels, which shape the cardiac action potential. Ionised magnesium is required to 
regulate intracellular calcium concentration by influencing calcium-ATPase (Ca - 
ATPase) pumps, sodium/calcium exchange systems and voltage-gated calcium 
channels, which are essential for contraction of heart muscle. Ionised magnesium
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activates adenyl cyclase and phosphodiesterase and therefore controls cyclic AMP 
concentration, which in turn regulates the activity of these transport systems (115).
The heart with its dense mitochondrial structure and high enzymatic activity is 
particularly vulnerable to magnesium loss. Magnesium deficiency due to diet or 
abnormalities in magnesium metabolism has been shown to play an important role in 
disease states such as ischaemic heart disease (IHD) and acute myocardial infarction 
(AMI), cardiac arrhythmias, hypertensive vascular disease and atherosclerosis (9, 86).
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1.2 Distribution of total and ionised magnesium in the body
Table 1.2 shows the distribution of total and ionised magnesium in the adult human. 
The distribution and percentage of total and ionised magnesium varies among the 
tissues of the body. Approximately 52.9% of total magnesium (TMg) is present in bone 
(37), 27.0% in muscle, 19.3% is present in soft tissue, 0.5% in red blood cells, and 0.3% 
in serum (50, 98). The distribution of EMg shows 54.6% in muscle, 38.2% in soft 
tissue, 1.4% in red blood cells, and 5.8% in serum (50). From values seen in different 
studies, the mean TMg concentrations have been found to range from 0.75 -  1.50 
mmol/L in serum, 2.3 -  2.7 mmol/kg in red blood cells, 8.3 -  8.7 mmol/kg in soft tissue, 
8.8 -  9.2 mmol/kg in muscle and 42.9 -  43.5 mmol/kg in bone (50, 80, 98). From these 
studies, serum IMg concentrations have been found to range from 0.50 -  0.65 mmol/L 
(used in subsequent chapters). This agrees with the values established in this study of 
0.56 ± 0.05 mmol/L (from 100 normal, healthy individuals). Furthermore, IMg 
concentrations have been reported to range from 0.19 -  0.23 mmol/kg in red blood cells, 
0.48 -  0.52 mmol/kg in soft tissue and 0.52 -  0.56 mmol/kg in muscle (12, 50, 84, 88, 
105).
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Table 1.2















0.50 -  0.65 
(0.58) 2.6 1.71 67.1 0.3 5.8
Red Blood 
Cells
2.3 -  2.7 
(2.5)
0.19-0.23
(0.21) 5.0 0.42 8.4 0.5 1.4
Soft Tissue 8.3 -  8.7 (8.5)
0.48 -  0.52 
(0.50) 193.0 11.35 5.9 19.3 38.2
Muscle 8.8 -  9.2 (9.0)
0.52-0.56
(0.54) 270.0 16.20 6.0 27.0 54.6
Bone 42.9-43.5(43.2) - 530.1 - 52.9 -
Adapted from references (12, 50, 80).
In most tissues magnesium is normally found in three states, approximately 33% is 
bound to plasma proteins (predominantly albumin), approximately 12% is complexed to 
small anions (e.g. bicarbonate, phosphate, or sulphate), and 55% in ‘free’, biologically 
active, ionised form (98). These three fractions, routinely measured as TMg, are in an 
equilibrium that can be altered by in vivo processes. As with other blood electrolytes, 
the physiological action of magnesium is related only to the activity of IMg. 
Because changes in IMg concentration are not necessarily reflected as changes in TMg 
concentration (17, 24, 91, 98), direct measurement of EMg may be clinically more useful 
than measurement of TMg (50).
Chapter 1 -  The role of ionised magnesium in cardiovascular function Page 6
AND PATHOLOGY
1.2.1 Absorption and Excretion of Magnesium
Approximately 35 -  40% of the ingested magnesium is absorbed via the jejunum and 
ileum (6, 82). Under normal physiological conditions, the kidney is the prime regulator 
of magnesium balance in the body. Approximately 5% -  10% of the filtered load is 
excreted by the kidneys (120). About 25 % of the filtered magnesium is reabsorbed in 
the proximal tubule and approximately 60% in the loop of Henle, by mechanisms still 
unknown (15). Consequently, malfunctioning kidneys are one of the most frequent 
causes of magnesium abnormality. Table 1.3 summarises several physiological and 
pharmacological factors that influence renal handling of magnesium.
Table 1.3
Physiological and pharmacological factors influencing renal 
handling of magnesium.
Factors stimulating Mg2+ reabsorption Factors inhibiting Mg2+ reabsorption
Low plasma Magnesium High plasma Magnesium
Low plasma Calcium High plasma Calcium
Parathyroid Hormone Salt, osmotic diuresis (Alcohol, Loop diuretics, etc)
Calcitonin Gentamicin
Antidiuretic Hormone Cyclosporine
Reproduced from reference (15).
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1.2.1.1 Magnesium deficiency
Several clinical and experimental trials, which are discussed below (Sections 1.5.1, 
1.5.2, 1.5.3 and 1.5.4), have shown that magnesium deficiency, rather than excess, leads 
to various cardiovascular disease states (33). Table 1.4 lists some causes of clinical 
hypomagnesaemia. Potential causes of low serum and tissue magnesium concentrations 
include excessive gastrointestinal losses, renal losses, and endocrine disorders. 
Gastrointestinal factors include alcoholism, diarrhoea, and malabsorption. Renal losses 
of magnesium are associated with acute renal failure, hyperthyroidism and in some 
circumstances are drug induced. Diuretic, cyclosporine, and antibiotic (e.g. Gentamicin 
and Ticarcillin) therapy have been associated with cases of severe hypomagnesaemia 
(116). Digoxin, a drug often prescribed to control cardiac arrhythmias, promotes 
magnesium depletion by inhibiting renal tubular reabsorption of magnesium, resulting 
in increased urinary excretion (24). Endocrine disorders with renal loss of magnesium 
include diabetic ketoacidosis, hyperparathyroidism, and hyperaldosteronism. Excessive 
lactation, exchange transfusions, and acute intermittent porphyria can also cause 
excessive magnesium loss (98, 126).
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Table 1.4
Causes of clinical hypomagnesaemia
Category Causes of clinical hypomagnesaemia
Gastrointestinal Alcoholism
Diarrhoea
Short bowel syndrome 
Malabsorption
Acute and recurrent pancreatitis
Renal Diuretics
Antibiotics (ticarcillin, gentamicin, carbenicillin)
Cisplatin
Cyclosporine
Hypercalcaemic states (including malignancies) 
Acute tubular necrosis (diuretic phase) 
Aldosteronism




Miscellaneous Excessive lactation 
Exchange transfusion 
Acute intermittent porphyria
Reproduced from references (57, 151).
A striking finding reported by a number of authors is that a magnesium-deficient state 
may coexist with normal serum TMg (24, 91, 98). Recent studies have shown 
significant depression (20% to 45%) of serum IMg concentrations in patients with a 
variety of coronary heart diseases and myocardial ischaemic syndromes (e.g. unstable 
angina pectoris, sudden death ischaemic heart disease, and cardiomyopathies), despite 
normal TMg levels (45, 82, 100, 151). Several distinctions have been made between 
IMg and TMg concentrations, which may help to explain these inconsistencies. Total 
magnesium is more stable than IMg and essentially independent of the equilibrium. It is 
an indirect assessment of magnesium status, since it includes all the inactive fractions.
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On the other hand, IMg concentrations fluctuate depending upon physiological 
conditions and therefore are a direct indicator of magnesium status (50).
1.3 Transport of ionised magnesium across cell membranes
The above-mentioned diverse functions of magnesium are mediated in part via changes in 
intracellular IMg concentrations. The mechanisms involved in IMg transport across the 
membrane of myocardial cells remain obscure. Several authors report that IMg influx 
may occur via a specific magnesium channel, or through other channels, such as the slow 
calcium channels (61, 152). However, this has yet to be proven. Similarly, the outward 
movement of IMg through the myocardial cell membrane is a matter of dispute. The lipid 
bilayer of the cell membrane is highly impermeable to charged molecules (ions) and 
therefore IMg cannot simply diffuse into the cell (7). Several authors have reported the 
presence of sodium/magnesium (Na+/Mg2+) antiport systems. A Na+/Mg2+ antiport 
system is a membrane transport carrier protein that functions by transferring magnesium 
ions across the lipid bilayer of a membrane by simultaneously transferring sodium ions in 
the opposite direction (31, 55, 102). For example, the Na+/Mg2+ antiporter has been 
observed to exchange one magnesium ion (out of the cell) for three sodium ions (into the 
cell) (56, 63, 93, 101, 117). Figure 1.1 is a schematic diagram showing the Na+/Mg2+ 
carrier protein functioning as an antiport system.
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Na /Mg carrier protein functioning as an antiporter
Figure 1.1
Reproduced from reference (7).
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1.4 The role of ionised magnesium in cellular processes and
CARDIOVASCULAR FUNCTION
1.4.1 Ionised Magnesium and Adenosine Triphosphate
ATP is present in all cells of living organisms. Most of the processes accompanied by 
changes in free energy that take place in living organisms are due to the synthesis or 
breakdown of ATP. Within cells, all enzymatic reactions that involve ATP show an 
absolute requirement for IMg. Adenosine triphosphate forms a complex with IMg, 
magnesium-ATP (Mg2+-ATP), with magnesium binding to the phosphate moiety. 
Figure 1.2 shows the structure of the Mg2+-ATP complex. Magnesium has a single 
divalent state and does not form highly stable chelates with organic complexes. It is this 
quality that allows IMg to act as a bridge in a large number of chemical reactions, 
resulting in the transfer of organic groups from one molecule to another (25).
Figure 1.2
The structure of the Mg2+-ATP complex.
Mg2+
O' O' O' Adenine
0 - -  P —  o - -  P —  o --  p - -  O —  Ribose
II II IIo o 0
Reproduced from reference (90).
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The importance of IMg in cellular metabolism is nowhere more obvious than in 
glycolysis (Figure 1.3). Glycolysis is the process by which glucose molecules are 
enzymatically degraded in a sequence of ten enzyme-catalyzed reactions to yield ATP 
and pyruvate. The substrate binding sites of many of the glycolytic enzymes appear 
specific for the magnesium complexes of the phosphorylated intermediates. Ionised 
magnesium forms complexes with phosphate groups of the glycolytic intermediates and 
of adenosine diphosphate (ADP) and ATP. For example, in the first step the glucose 
molecule is primed for subsequent reactions to yield glucose 6-phosphate at the expense 
of ATP. This reaction is catalysed by hexokinase, which requires IMg because the true 
substrate of the enzyme is not ATP but the Mg2+-ATP complex (32).
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Magnesium dependent enzymes are underlined. Reproduced from reference (32).
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Inside the mitochondria, the Krebs cycle acts as the final common pathway for the 
oxidation of carbohydrates, lipids and proteins (Figure 1.4). Ionised magnesium is an 
important component of the decarboxylation reaction and several of the essential 
enzymes in this pathway are magnesium-dependent (27).
Figure 1.4




























Magnesium dependent enzymes are underlined. Adapted from reference (27).
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Furthermore, IMg is necessary for oxidative phosphorylation of ADP and adenosine 
monophosphate (AMP). Within the mitochondria, the energy rich molecules of 
nicotinamide adenine dinucleotide (NAD) and flavin adenine dinucleotide (FAD) 
formed from glycolysis, Krebs cycle etc, generate the high-energy intermediate ATP 
(Oxidative Phosphorylation). They are oxidised by the cytochrome system, where 
electron migration between NAD and FAD, and the cytochromes is stimulated by 
magnesium, to form ATP (27).
Moreover, IMg serves to regulate the energy source (ATP) available for muscular 
contraction. When muscle contracts, ATP is consumed to form ADP. Creatine kinase 
catalyses the rephosphorylation of ADP to form ATP. Heart and skeletal muscle also 
store high-energy phosphates temporarily in the form of creatine phosphate. Creatine 
phosphate acts as a backup store for rapid regeneration of ATP when levels fall because 
of increased demand. Figure 1.5 illustrates how creatine kinase catalyses the reversible 
transfer of a phosphoryl group from creatine phosphate to ADP to form ATP. 
Ionised magnesium plays an essential regulatory role in the way creatine kinase 
(creatine kinase -  MB fraction (CK-MB) in the heart muscle) functions. 
Aukawa (25) reported that with low physiological magnesium concentration creatine 
phosphate is preferentially synthesised, while high physiological magnesium 
concentration preferentially generate ATP. Therefore, the EMg concentration 
effectively serves to regulate the rates of forward and reverse reactions, keeping the 
concentration of ATP constant.
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Creatine phosphate transfer of phosphate group to ADP to form ATP.
Figure 1.5
j|W j|p j H CH3
— C — N — CH2— C — O Creatine Phosphate
B I B  NH2 O
+
ADP
Mg 2+ Creatine Kinase
H CH3
H — N — C— N — CH2— C — O' Creatine
I II
n h 2 o
+
ATP
CHAPTER 1 -  THE ROLE OF IONISED MAGNESIUM IN CARDIOVASCULAR FUNCTION Page 17
AND PATHOLOGY
1.4.2 Effect of Ionised Magnesium on Ion Channels
1.4.2.1 Ionised magnesium regulates the cardiac action potential
The electrical activity of the myocardial cell and the specialised electrical conduction 
system of the heart are derived from the ability of the cell to alter the electro-chemical 
gradient across the cell membrane, or sarcolemma (115). Most animal cells have a high 
intracellular concentration of potassium (K+) and a low intracellular concentration of 
sodium (Na+) relative to the external medium. Transmembrane movement of ions 
(primarily sodium, potassium and calcium) sequentially depolarise and repolarise the 
cell membrane resulting in an action potential. The active transport of sodium and 
potassium is therefore of great physiological significance. More than a third of the ATP 
consumed is used to pump these ions across the cell membrane (7).
Figure 1.6 is a schematic representation of three different Na+/K+ channels and pumps 
that are regulated by IMg. The Na+/K+ ATPase pump (Fig. 1.6A) operates as an 
antiporter, actively pumping sodium out of the cell against its steep electrochemical 
gradient and pumping in potassium (7). This enzyme is dependent on IMg as a cofactor 
and derives its energy from hydrolysis of Mg2+-ATP. Each ATPase contains a catalytic 
subunit, which is sequentially phosphorylated and dephosphorylated during the 
pumping cycle (7). Consequently, IMg helps to maintain the transmembrane gradients 
of sodium and potassium that determine the electric potential across the cellular 
membrane. Mclean et al (98) reports that deficiency in magnesium may result in 
neuromuscular excitability and irritability as alterations in sodium/potassium gradients 
and transmembrane potential occur.
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Ionised magnesium’s role in three different ion channels and pumps.
Figure 1.6
Cation Channels
Reproduced from references (5,7).
Similarly, voltage-gated potassium channels (Fig. 1.6B) and acetylcholine-gated 
potassium channels (Fig. 1.6C) are also responsible for the maintenance of the resting 
potential and generating the plateau of the action potential in the plasma membrane of 
all electrically excitable cells (e.g. muscle, neurons and endocrine cells) (5). 
Voltage-gated potassium channels open so that the transient influx of sodium is rapidly 
overwhelmed by an efflux of potassium, driving the membrane back toward the 
potassium equilibrium potential. Acetylcholine-gated potassium channels are opened 
by acetylcholine binding to receptors on the myocyte plasma membrane. 
Unlike voltage-gated potassium channels, acetylcholine-gated cation channels have 
little selectivity among cations and so the normal traffic consists of sodium, potassium 
and some calcium. Ionised magnesium regulates the activity of these channels by
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blocking the opening when the cell becomes polarised -  depolarisation removes 
magnesium and the channels open (5, 68, 96). Matsuda and co-workers have shown 
that when magnesium concentrations are reduced, the inward rectifying properties of the 
potassium channels are lost (96). Similarly, in mammalian atrial and ventricular 
myocytes, Agus et al (5) report that in the absence of intracellular magnesium, the 
current/voltage relationship of these channels is virtually linear. In other words, when 
intracellular magnesium is reduced to zero, potassium ions are carried equally in both 
directions across the membrane. Losses of cytoplasmic magnesium together with 
potassium efflux are two of the earliest signs of ischaemic injury (5).
1.4.2.2 Ionised magnesium regulates myocardial contractility
Ionised magnesium serves to regulate intracellular calcium concentrations and therefore 
regulate myocardial contractility. Three possibilities have been reported for the 
regulation of calcium; they are the calcium ATPase (Ca -ATPase) pumps, 
sodium/calcium (Na+/Ca2+) antiport systems (74, 123) and voltage-gated calcium 
channels.
Entry of calcium into heart muscle cells, however small, is believed to help trigger 
release of calcium stored in the sarcoplasmic reticulum, which in turn initiates muscle 
contraction (99, 117). Calcium ions are pumped out from the sarcoplasmic reticulum 
through membrane bound Ca2+-ATPase pumps, flooding the cytosol and initiating the 
contraction of each myofibril. The increase in calcium concentration in the cytosol is 
transient because calcium is pumped back into the sarcoplasmic reticulum by the
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reverse action of Ca2+-ATPase (64, 83, 123). Restoration of the cytosolic calcium 
concentration causes the myofibrils to relax. The activity of Ca2+-ATPase derives its 
energy from hydrolysis of Mg2+-ATP. Magnesium thus serves to regulate calcium 
handling by the sarcoplasmic reticulum (74). Furthermore, after a contraction, excess 
calcium has been reported to be removed from the cell by Na+/Ca2+ antiport systems 
(Fig. 1.1 above is an example of an antiporter) (123). Calcium efflux is compensated by 
the entry of three sodium ions into the cell through the Na+/Ca2+ antiport system. 
Mg2+-ATP provides the energy necessary for this exchange (123).
Ionised magnesium has also been found to regulate calcium influx into the myocyte 
through sarcolemmal voltage-gated calcium channels (115). Voltage-gated calcium 
currents play a major role in the development of the cardiac action potential, in the 
generation of electrical pacemaking in nodal tissue, and in the initiation of muscle 
contraction. When the cell becomes polarised, intracellular IMg has a blocking effect 
on the calcium current -  depolarisation removes magnesium and the channels open. 
(24). The role that IMg serves by regulating voltage-gated calcium currents can explain 
some of the pathological effects of magnesium deficiency in the heart. When normal 
processes that maintain low intracellular calcium concentrations are interrupted 
(for example, during ischaemia), increases in voltage-gated calcium currents produced 
by loss of intracellular IMg may contribute to calcium overload and myocardial damage 
(123).
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Ionised magnesium also affects myocardial contractility by modulating the second 
messenger system, adenylate cyclase-cyclic AMP (cAMP) (136). Membrane-bound 
ATPases as well as the slow calcium channels of the heart, are stimulated by cAMP 
(136). The formation of cAMP from ATP is catalysed by a plasma membrane-bound 
enzyme, adenylate cyclase. Cyclic AMP is rapidly and continuously destroyed by 
phosphodiesterases present in the cell. Elevation of cAMP produces a very large 
increase in the number of opened ATPase and slow channels available (136). 
Therefore, any agents that increase the cAMP level of the myocardial cell will initiate 
calcium influx and contraction (115). Hence, increase and decrease in cAMP 
concentrations participate in coronary vasodilatation and constriction, respectively (13). 
Ionised magnesium has been shown to activate both adenylate cyclase and 
phosphodiesterase activity and therefore controls cAMP production (13, 98).
Altogether, a 10,000-fold intracellular to extracellular calcium gradient is created and 
maintained by these pumps and channels, which is crucial to muscle contraction (134). 
In a simplified model, Iseri et al (74) reports that a reduction in magnesium would let 
too much calcium into the muscle cell, thereby prolonging contraction and resulting in 
abnormalities such as hypertension, neurologic deficits, ischaemia and stroke. 
On the other hand, an increase in magnesium would reduce contraction and lead to 
hypotension, peripheral respiratory muscle paralysis, and bradycardia. Consequently, 
the normal contraction of cardiac muscles relies on the activity and availability of IMg 
and may form the basis of a variety of cardiovascular disease states.
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1.5 Magnesium and cardiovascular disease
1.5.1 Hypertension
Given its physiological roles in the cardiovascular system it is not surprising that 
magnesium deficiency has been implicated in the genesis of hypertension. 
Animal studies provide evidence that lowering magnesium concentrations can result in 
hypertensive events (15, 16, 89, 122). The mechanism of how magnesium regulates 
blood pressure appears to be complex and includes inhibition of vasodilatory 
prostaglandin release, regulation of calcium ion flux into the cell, and antagonising the 
action of vasoconstrictors such as noradrenaline and angiotensin (141).
Altura et al (16) report that dietary deficiency of magnesium in rats results in the 
elevation of arterial blood pressure, decreases in arteriolar, venular, and precapillary 
lumen sizes, and decreased number of microvessels with a concomitant decrease of 
blood flow in capillaries. An inverse relationship between lumen size and serum IMg 
concentrations was found. Figure 1.7A represents vascular smooth muscle tone under 
conditions of normal extracellular ionised magnesium and calcium concentrations. 
As the ratio of calcium-to-magnesium increases (Fig. 1.7B), lumen size decreased and 
contractile tension increased. Elevations of IMg concentrations above the physiological 
level lowered baseline tension (Fig. 1.7C) (11, 122). Together, these findings suggest 
that the concentration of IMg in the extracellular fluid, in vascular muscle cells and at 
the vascular smooth muscle cell membrane has a significant role in controlling vascular 
tone, contractility of blood vessels and subsequent prevention of hypertension (9).
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The effects on vascular smooth muscle of changes in extracellular 
ionised magnesium concentration.
Figure 1.7
Changes in extracellular IM g concentration have direct effects on vascular sm ooth m uscle tone. 
N orm al vascular sm ooth m uscle tone (A). Decreases in extracellular IM g raise contractile 
tension (B) w hile elevations above the physiological level lowers baseline tension (C). 
R eproduced from  reference (10).
Clinical studies demonstrate that patients with hypertension also exhibit 
hypomagnesaemia in serum and/or tissues. On average, patients with long term 
hypertension have at least a 15% deficit in serum TMg (11). Inverse relationships 
between total serum or tissue magnesium concentrations and arterial blood pressures 
have been reported by a number of studies (15, 24, 43, 115, 126). Furthermore, these 
authors demonstrate that intravenous infusion, or oral administration of magnesium salts 
lowers the arterial blood pressure in hypertensive patients (14, 15, 24, 43). 
For example, Altura et al (14) reports that the oral magnesium supplementation to 
hypertensive patients with significant hypomagnesaemia lowered systolic and diastolic 
blood pressures by up to 35 and 15 mm Hg, respectively. Moreover, they also stated 
that there was a 15% decrease in serum IMg levels even in patients with borderline 
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hypertension whilst serum TMg levels remained unchanged. This again emphasises that 
the assessment of TMg as a guide for the therapeutic efficacy may not be reliable in all 
cases. In a double blind placebo controlled study by Dyckner et al (47), patients on 
chronic diuretic therapy were randomised to receive either magnesium or placebo. 
Oral administration of magnesium to 20 patients on chronic diuretic therapy caused a 
drop in blood pressure of 12/8 mm Hg at 6 months. The placebo group experienced a 
drop in diastolic pressure of 4 mm Hg with no change in systolic pressure at 6 months. 
The results from these studies demonstrate that magnesium supplementation may be of 
value as an alternative to anti-hypertensive drug therapy.
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1.5.2 Atherosclerosis
Hypercholesterolaemia is widely accepted as a strong risk factor for the development of 
both atherosclerosis and ischaemic heart disease. The focal accumulation of lipids, 
complex carbohydrates, blood and blood products, fibrous tissue, and especially 
calcium deposits in an artery, results in atherosclerosis (126). However, it remains 
unclear how lipoproteins, calcium, and macrophages gain access to the normally 
impermeable arterial walls, resulting in the loss of contractility of vascular smooth 
muscle. Evidence from both human and animal studies suggests that IMg may play a 
role in regulating serum levels of lipids and lipoproteins (11, 111). Lower magnesium 
intake is correlated with higher serum lipid levels (11). However, the mechanism of a 
possible interaction between magnesium and lipid metabolism remains to be elucidated.
Several studies have confirmed that magnesium deficiency can intensify cardiovascular 
lipid deposition and lesions and that dietary magnesium supplementation prevents 
atherosclerosis (11, 111). Altura et al (11) have demonstrated that pre-treatment of 
animals (rats and dogs) with developing atherosclerosis by administration of magnesium 
had beneficial effects. Considerable lowering of serum cholesterol and triglycerides 
occurred in normal as well as atherosclerotic animals. In addition, compared to 
controls, pre-treatment reduced the atherosclerotic process markedly and reduced 
calcium in the arterial walls. These findings suggest that IMg plays an important 
regulatory role in controlling lipid metabolism in arterial walls (15).
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Furthermore, both in vivo and in vitro studies indicate that magnesium deficiency 
affects the susceptibility of lipoproteins to peroxidation, resulting in the formation of 
lipid peroxidation products. Oxidised lipoproteins (e.g. oxidised very-low-density 
lipoproteins and low-density lipoproteins) have been shown to be cytotoxic to cells in 
culture (15). Altura et al (15) reports that these lipid peroxidation products appear in 
rats and hamsters within a week after the initiation of a magnesium deficient diet. 
Within 2 - 3  weeks, cardiomyopathic lesions appear to become prominent in both 
animal models. Moreover, it has been shown that magnesium deficiency causes an 
elevation in circulating levels of the inflammatory cytokines such as interleukin-1, 
interleukin-6 and tumour necrosis factor-alpha, and endothelin concomitant with the 
appearance of lipid peroxidation and myocardial damage (11, 110, 112). Collectively 
this data suggest that magnesium deficiency significantly contributes to the vascular 
injuries seen in atherogenesis and hypertensive disease that often leads to ischaemic 
heart disease (110).
Clinical studies have shown that the thrombotic tendencies in atherosclerosis play 
important roles in the “cracking and bleeding” of atherosclerotic plaques in patients 
with LHD and AMI (11). High concentrations of magnesium have been demonstrated to 
suppress thrombus formation. Several authors report that high doses of intravenous 
administered magnesium can markedly decrease platelet aggregation at the site of 
arterial constriction, and prevent formation of microthrombi in animals with narrowed 
major coronary arteries (11, 27, 126, 148).
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1.5.3 Arrhythmias
Although there are several physiological effects of altered IMg levels in myocardial 
tissue that may produce arrhythmias, the mechanism for the loss of normal cardiac 
rhythm in arrhythmias is not fully understood. As described earlier, IMg is an essential 
activator of the Na+/K+ ATPase pump, helping to maintain the resting potential across 
the cell membrane (24, 26). Magnesium deficiency is associated with loss of 
intracellular potassium, an increase in intracellular sodium and an increase in cell 
membrane excitability. An increase in intracellular sodium increases sodium-calcium 
exchange, with a rise in intracellular calcium. The result is transient depolarisation of 
the cell membrane and repetitive arrhythmias (49, 149, 150).
Figure 1.8 is a schematic representation of electrocardiograms in patients with normal 
(A), moderately (B) and severely (C) lowered serum TMg levels. The electrocardiogram 
is a record of the electrical activity of the heart and is a valuable tool for detecting 
abnormal cardiac rhythm and myocardial damage. The electrocardiogram gives 
important information concerning the spread of excitation of the different parts of the 
heart. Depolarisation of atrial muscle tissues cause atrial contraction generating a 
so-called P wave. The Q, R and S waves (QRS complex) correspond to a wave of 
depolarisation across the ventricular muscle. The T wave corresponds to ventricular 
repolarisation (42).
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Comparison of electrocardiograms from patients with normal (A), 
moderately (B) or severely lowered (C) serum total magnesium levels.
Figure 1.8
Reproduced from references (42, 126)
Patients with mild magnesium deficiency (serum TMg of < 0.70 mmol/L; normal range 
0.70 -  0.90 mmol/L) exhibit a widening of the QRS complex, an increase in peak T 
waves (Fig. 1.8B), and ST segment depression (Fig. 1.8C). The more severe the 
magnesium deficiency (TMg of < 0.65 mmol/L), the wider the QRS complex becomes 
(Fig. 1.8C) and arrhythmias occur (128). The QT interval (i.e. beginning of the QRS 
complex to the end of the T wave) which represents the total duration of ventricular 
systole is delayed in magnesium-deficient patients (24). It is during this period that the 
patient is highly vulnerable to cardiac arrhythmias resulting in myocardial infarction 
and possible death (25, 149). Table 1.5 summarises various kinds of arrhythmias 
caused by low magnesium levels.
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Table 1.5
Various kinds of arrhythmias caused by low magnesium levels.
Ventricular tachycardia 
Ventricular fibrillation 
Torsade de pointes 
Digitalis-induced arrhythmias 
Paroxysmal atrial tachycardia 
Atrial flutter and fibrillation 
Multifocal atrial tachycardia
Reproduced from reference (149)
Extensive clinical trials have been carried out in patients with AMI to investigate the 
value of treating arrhythmias with magnesium (29, 39, 69, 104, 109, 130, 132, 138, 146, 
148). In each double-blind placebo-controlled study, patients with suspected AMI were 
randomised to receive either magnesium or placebo immediately on admission to 
hospital. These studies concluded that there are significant reductions of complex 
arrhythmias in patients treated with magnesium. On average, 44% of patients from the 
placebo groups exhibited arrhythmias, compared to only 24% in the group given 
magnesium. In addition, the latter group had a 49% reduction in the incidence of 
ventricular tachycardia and fibrillation. A further striking finding in these studies was 
the higher mortality rate (from 2% to 14%) in the placebo group.
Chapter 1 -  The role of ionised magnesium in cardiovascular function Page 30
AND PATHOLOGY
1.5.4 Ischaemic Heart Disease and Acute Myocardial Infarction
Myocardial ischaemia, or inadequate blood flow to the heart, may lead to angina 
pectoris and myocardial infarction (i.e. a condition caused by partial or complete 
occlusion to one or more of the coronary arteries) (137). There are many causes of 
IHD, but the most common cause is coronary atherosclerosis (126, 137).
The available data suggest that deficiency in cardiac and vascular tissue IMg does play a 
role in the aetiology of atherosclerosis, arrhythmias and hypertension. Thus, it would be 
anticipated that a large number of patients with IHD and AMI would have blood, 
cardiac and vascular tissue deficiency of magnesium. However, the prevalence of 
magnesium deficiency in patients with ischaemic heart disease and acute myocardial 
infarction has not yet been well established. Several reports indicate that serum TMg 
concentrations are reduced in patients with AMI (58, 108), while other studies have 
observed normal serum TMg concentrations (78). Ott et al (104) concluded in a review 
that hypomagnesaemia associated with AMI may be transient, and serum TMg 
concentration may become normal after the acute phase of AMI (109, 132). 
Nevertheless, the most consistent data has been noted in cardiac tissue of patients who 
died of sudden death ischaemic heart disease. In these patients, a mean 20% loss of 
TMg in cardiac tissue has been reported (15,40,49, 144).
Current studies have revealed that a great deal of the inconsistencies in published 
reports has been due to the inability to measure serum IMg. Recent reports by Altura et 
al (8, 10) clearly demonstrate for the first time, consistent deficits in serum IMg in
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many IHD patients. In a double-blind study Altura et al (8) have shown that a high 
incidence of hospitalised patients clearly exhibit low serum IMg levels. For example, 
83% of patients admitted with coronary artery disease and AMI exhibited low serum 
IMg, but normal serum TMg.
1.5.4.1 Magnesium as a pharmacological agent in acute 
myocardial infarction
Acute myocardial infarction is another condition for which randomised and placebo­
controlled trials of magnesium therapy have been undertaken. Currently, the 
pharmacological role of magnesium in myocardial infarction remains controversial, 
with further studies needed (127). Different studies (of up to 1,300 patients per study) 
have reported little or no benefit to as much as an 89% reduction in the short-term 
mortality rate after magnesium infusions, in patients with suspected AMI (1, 39, 67, 69, 
70, 87, 109, 130, 133, 138, 146). The Second Leicester Intravenous Magnesium 
Intervention Trial (LEMIT-2) (2,316 patients) showed that magnesium infusion has 
clinical efficacy (153, 154). Table 1.6 summarises the protocol and findings of the 
LIMIT-2. The trial reported a 24% reduction in 28-day mortality in patients with AMI 
treated with magnesium. Magnesium-treated patients also had a 25% lower incidence 
of congestive heart failure, suggesting that magnesium has a direct protective effect on 
the myocardium. Moreover, the long term results from LIMIT-2 revealed a 21% lower 
rate of ischaemic heart disease in the magnesium-treated group over 4 years (20, 148).
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Table 1.6





Study design Double-blind, placebo 
controlled






Dose 8 mmol loading dose over 5 
minutes, plus 65 mmol infusion 
over 24 hours.
8 mmol loading dose over 15 
minutes, plus 72 mmol infusion 
over 24 hours
Timing requirements Loading dose before any 
thrombolysis
Randomised after completion of 
lytic phase*
Median time from the 
Onset of symptoms to 
randomisation




25% relative reduction in LVF 
in CCU (P = 0.009).
24% relative reduction in 28-day 
mortality in magnesium group 
(P = 0.04)
16% decrease in all-cause 
mortality at 1.0-5.5 (mean 2.7) 
years in magnesium group 
(P -  0.03)
5.5% relative increase in 5-week 
mortality in magnesium group 
(2P = 0.07)
0.36% mortality excess at 
median 15 months in 
magnesium group
The first hour or so of any fibrinolytic regimen. LVF = left ventricular failure; 
CCU = coronary care unit. Adapted from reference (28,131).
Contrary to the LIMIT-2 study, the Fourth International Study of Infarct Survival 
(ISIS-4) study of 58,050 patients found no improvement in short-term mortality rates 
following magnesium therapy in patients with AMI (75, 76). Table 1.6 summarises the 
protocol and findings of ISIS-4. The mortality rate was 7.6% in the magnesium treated
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group and 7.2% in the control group, suggesting no mortality benefit of magnesium 
administration (75, 76, 126).
Several important differences between the protocols used in ISIS-4 and LIMIT-2 have 
evoked controversy. The timing of magnesium administration and thrombolytic 
treatment are two major differences between trials that may explain the disparities in 
results. LIMIT-2 protocol specified that magnesium infusion be started as soon as 
possible after onset of symptom and that in cases where a fibrinolytic agent was used, it 
was to be provided after or at the same time as the magnesium infusion. Woods et al 
(154) attributed the 24% reduction in the 28-day mortality in LIMIT-2 to the prompt 
administration of magnesium before thrombolysis. Furthermore, early magnesium 
treatment reduced left ventricular failure, which may explain the 21% reduction in 
mortality over a mean follow-up of 2.7 years. ISIS-4 protocol on the other hand called 
for administration of a magnesium infusion from several hours up to 12 hours after 
commencement of thrombolytic therapy (127). Even slight delays in administering 
magnesium may have lessened its beneficial effects.
The dosage of magnesium in the first 24-hour after AMI may also contribute to the 
differences between the two trials. The administration of magnesium at a level greater 
than the therapeutic threshold can cause hypermagnesaemia. Generalised vasodilation 
due to hypermagnesaemia can cause profound hypotension, which could increase risk of 
shock and extension of myocardial necrosis (59, 129). In the LIMIT-2 study, 
magnesium dosage was 73mmol/24hr and hypermagnesaemia was not a problem.
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However, in the ISIS-4 study the magnesium dosage was 80 mmol/24hr, and 
hypotension was significantly more frequent in patients treated with magnesium than in 
the control group. Thus, the amount of magnesium infused over 24 hours could be 
another factor affecting morbidity and mortality.
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1.6 Project aims
Survival of patients with AMI is dependent on the quick and accurate diagnosis. 
A rapid diagnosis improves the physician’s ability to minimise cardiac damage by 
thrombolytics or emergency surgery. However, in a large percentage (approximately 
30%) of patients with chest pain, the correct detection or exclusion of AMI depends 
entirely on biochemical tests such as CK-MB and ECG recordings.
Serum magnesium concentrations have been reported by a number of authors to 
decrease in patients with AMI (2, 14, 34, 35, 46, 58, 66, 72, 113). If so, the 
measurement of serum or whole blood IMg in a clinical setting may be a cost-effective, 
simple and rapid means of providing an accurate diagnosis. With the development of 
ion selective electrodes, it is now possible to measure the ionised or biologically active 
form of magnesium in urine, plasma, serum and whole blood.
The aims of this study are:
(i) to validate the analytical precision of the AVL 988-4 analyser’s magnesium ion 
selective electrode (Chapter 2).
(ii) to determine the effects of duration and temperature of storage on the stability of 
IMg in serum and whole blood samples (Chapter 3).
(iii) to measure IMg, TMg and CK-MB in non-AMI and AMI groups, to evaluate 
any trends in IMg associated with AMI, and to determine if IMg concentrations 
could be used as a diagnostic tool for AMI (Chapter 4).
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C h a p t e r  2 -
A n a l y t ic a l  p r e c isio n  o f  th e
A V L  988-4 ANALYSER FOR 
MEASURING IONISED MAGNESIUM
2.1 Introduction
Understanding of magnesium metabolism in health and disease has been compromised 
by the lack of appropriate technology to determine IMg. Several technologies that have 
recently emerged for determining IMg concentrations in tissue and body fluids include 
Nuclear Magnetic Resonance Spectroscopy (NMRS), Fluorescent Probes (FP) and Ion- 
Selective Electrodes (ISE).
NMRS has been used to determine intracellular IMg in a variety of tissues (35, 92). 
This technique takes advantage of differences in NMR spectral characteristics of the 
two species of ATP (free ATP and Mg2+-ATP) present in the cell. By using a 31P probe, 
it is possible to distinguish and quantitate ATP and Mg2+-ATP (38, 124, 125). The 
estimation of intracellular IMg concentration is based upon measurement of the 
frequency differentiation between alpha phosphorus and beta phosphorous resonances 
and depends on the extent of complexation between magnesium and ATP (61). The 
accurate assessment of intracellular IMg concentration also depends on the choice of 
stability constant for Mg2+-ATP, which is still a matter of dispute (102, 117). Although 
extremely sensitive such a method is not currently cost-effective or sufficiently rapid for 
diagnosis of AMI.
FP are used to determine intracellular IMg concentration (107, 145). FP are compounds 
that selectively bind magnesium and concomitantly undergo spectral changes. Furaptra 
is a FP that exhibits a shift in the peak excitation wavelength for fluorescence when
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bound to magnesium. The change in fluorescence corresponds to the IMg concentration 
(44, 50).
It should be mentioned that changes in intracellular ATP or pH affect the complexation 
of magnesium and ATP (NMRS technique), and magnesium and the FP (FP technique), 
potentially giving incorrect readings (50, 51). This characteristic renders it difficult to 
use the above techniques for IMg determination during ischaemia where both 
intracellular pH and ATP change drastically.
Currently, ISE constitute the most suitable means for rapidly assessing IMg levels in 
clinical practice. ISE are relatively inexpensive potentiometric devices and are widely 
used for the routine monitoring of various analytes (e.g. calcium, potassium, chloride, 
magnesium and sodium) in serum, plasma and whole blood (103, 134). The fast and 
reproducible response that these electrodes exhibit can also provide real-time 
monitoring of these analytes in a clinical laboratory.
The ISE measurement principle is based on the measurement of a potential that 
develops across a selective membrane. The ion selective membrane separates the 
sample whose electrolyte concentration is unknown from an electrode solution whose 
electrolyte concentration is known. An ionophore (a chemical material that has a high 
affinity for a particular ion) incorporated into the ISE reacts selectively with the ion of 
interest. This in turn generates an electrochemical potential on both the outer membrane 
surface, which is exposed to the sample, and the inner membrane surface, which
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contacts the inner filling solution of the ISE. The potential of the inner surface of the 
membrane is kept constant whilst the only potential change measured in the circuit is 
the potential of the membrane surface in contact with the sample. Thus, the potential 
difference is related to the ion concentration in the sample (50, 51, 79).
Previous studies have shown that there are problems with IMg ISE that may affect their 
clinical usefulness (52, 53, 71, 114, 157). Apart from the limited lifespan of the IMg 
ISE, the major difficulty of the IMg ISE is the insufficient selectivity of the ionophore 
for IMg over other cations found in the plasma matrix, mainly ICa. To overcome this 
difficulty the instrument carries out a chemometric procedure, i.e. it measures ICa 
(adjusted to a normal pH of 7.4) and mathematically adjusts IMg for it.
If ISE measurement of EMg is to be useful for the diagnosis of AMI, the data obtained 
must be reproducible and accurate. At present three companies (AVL in Austria, 
KONE in Finland and NOVA in the United States) are developing an IMg ISE for 
clinical use. The AVL 988-4 analyser was used for this study as it had the longest ISE 
lifespan, the widest analytical range and required the least amount of sample and time 
for analysis.
The aim of this study was to verify previous precision studies on the AVL IMg ISE. 
In contrast to other precision studies that only used artificially produced quality control 
solutions (52, 71, 157), human serum samples were also used to evaluate precision.
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2.2 Materials and Methods
2.2.1 The AVL 988-4 Analyser
The AVL 988-4 analyser (AVL Medical Instruments, Melbourne, Australia Pty Ltd) 
containing the specially designed ionophore (neutral carrier ETH 7025), was used to 
obtain all IMg concentrations in this study. The analyser determines pH and the 
concentrations of IMg, ICa and ionised sodium (INa), in mmol/L. Six measurement 
(sample types) modes are available on the analyser, they are whole blood, serum, 
standard (calibrator), urine, dialysis solution and quality control materials. A 120 jiL 
sample is required to measure the four analytes, and results are available 90 seconds 
after sample introduction. The AVL 988-4 IMg ISE measures IMg concentrations 
ranging from 0.1 -  3.0 mmol/L.
The AVL 988-4 analyser has four standard solutions, namely Standard A, Standard B, 
Standard C and Standard D. Table 2.1 lists the concentration of each analyte in the 
supplied Standard solutions. A fully automatic 1-point calibration is performed with 
every measuring cycle, with multiple point calibrations performed every 3 hours. Every 
24 hours the analyser performs a 4-point calibration for IMg.
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2.2.2 Samples
To determine analytical precision three commercial protein-based control solutions and 
three human sera were used. The three protein-based control solutions (ISE-trol 1, ISE- 
trol 2, and ISE-trol 3 - Code HC0033) contained different concentrations of IMg, ICa, 
INa and pH. The concentrations of all analytes in the different solutions are given in 
Table 2.1.
Table 2.1







Standard A 0.30 0.90 150.0 7.38
Standard B 0.30 1.25 100.0 7.00
Standard C 0.90 0.90 150.0 7.38
Standard D 0.30 0.90 100.0 7.38
ISE-trol Level 1 0.98-1.28 1.92-2.22 117-123 7.19-7.25
ISE-trol Level 2 0.52 -  0.72 1.21-1.51 144-150 7.38 -  7.44
ISE-trol Level 3 0.24 -  0.40 0.55 -  0.75 158-164 7.62 -  7.68
Serum samples were! collected from 15 volunteers. Venous blood (7.5 mL) was
collected under anaerobic conditions by using the Monovette (Serum Gel) syringe
system (Sarstedt, Nümbrecht, Germany). The tubes contain no additives, except for an
inert gel layer that facilitates serum separation from the blood cells during
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centrifugation. Blood specimens were allowed to clot for 15 minutes at room 
temperature after collection before being centrifuged in a Labofuge GL (Heraeus-Christ, 
Gipsmuhlenweg, Germany) at 3500 rpm for 10 minutes. The IMg concentration was 
determined in each sample in duplicate, and three were selected to cover the widest 
analytical range possible. The three serum samples were identified as Serum A, B and 
C. The sera were kept in capped 5 mL cups for the within-run precision study or 
divided equally into 20 aliquots in capped 0.5 mL cups and frozen (-20 °C) for the day- 
to-day precision study.
Any haemolytic, icteric or turbid samples were discarded. Haemolysis (the breakdown 
of red blood cells) falsely increases serum concentrations of analytes that are present in 
high concentrations within the red blood cells, such as potassium and magnesium. 
Icteric or turbid samples are potential analytical interferents (79).
The AVL 988-4 analyser automatically corrects for any interference by ICa and 
calculates the ICa concentration adjusted to a normal pH of 7.4 for samples with pH 
between 7.2 to 7.6. Consequently, there is a close chemical relationship between the pH 
value of a blood sample and its ICa concentration. The pH value of a blood sample 
varies due to exchange of C02 with air. Hence, all samples needed to be kept in an 
anaerobic environment to avoid artefactually elevated pH values, and therefore, 
inaccurate ICa and IMg concentrations (36, 95, 122).
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2.2.3 Assessment
All samples were analysed only after maintenance, daily calibration and quality control 
procedures were performed on the AVL 988-4 analyser, as recommended by the 
manufacturer. Commercial protein-based control solutions (ISE-trols) and sera were 
analysed in a continuous randomised order 20 consecutive times to assess within-run 
precision. Analysing each protein-based control solution and sera in a randomised order 
on 20 consecutive days performed the day-to-day precision study. On each day a new 
ampoule of each protein-based control solution was opened and analysed immediately. 
As well, an aliquot of each frozen serum was thawed for 30 minutes, mixed by gentle 
inversion and analysed. For the protein-based control solutions, the AVL 988-4 
analyser was used in the Quality Control mode. For the sera, the analyser was used in 
the Serum mode.
2.2.4 Statistical Analysis
For each precision study, the mean, standard deviation (SD) and coefficient of variation 
(%CV) expressed as a percentage, were calculated for IMg for each protein-based 
control solution and serum sample.
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2.3 Results
The within-run and day-to-day precision of the AVL 988-4 analyser is shown in 
Table 2.2. For the protein-based control solutions, the standard deviations for within- 
run and day-to-day precision studies were <0.012 mmol/L, and <0.043 mmol/L, 
respectively. The %CV for within-run precision was <2.30%, and for day-to-day 
precision was <4.04%. For the sera, the standard deviations for within-run and 
day-to-day precision studies were <0.006 mmol/L, and <0.015 mmol/L, respectively. 
The %CV for within-run was <1.05 %, and for day-to-day precision was <2.76%.
The best within-run CVs were obtained for solutions that have IMg within or close to 
the physiological range (0.50 -  0.65 mmol/L). In comparison to the protein-based 
control solutions, the serum samples exhibit the lowest CVs in both within-run and 
day-to-day precision studies.
Table 2.2
Within-run and day-to-day precision of AVL 988-4 analyser for IMg.
Solution
IMg







ISE-trol 1 20 1.12 0.012 1.05 20 1.07 0.043 4.04
ISE-trol 2 20 0.61 0.006 0.98 20 0.56 0.018 3.15
ISE-trol 3 20 0.28 0.006 2.30 20 0.27 0.008 2.81
Serum A 20 0.45 0.005 1.05 20 0.44 0.012 2.76
Serum B 20 0.54 0.005 0.94 20 0.54 0.012 2.30
Serum C 20 0.60 0.006 0.95 20 0.60 0.015 2.50
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2.4 Discussion
This study compared the precision of the IMg ISE with the findings of other 
investigators. The precision of the AVL analyser for IMg in this study is consistent 
with four other reports also using the ISE-trol protein-based solutions. The study by 
Elin et al (52) of the AVL 988-4 analyser reported within-run and day-to-day CVs for 
IMg of <3.00% and <6.40%, respectively. In the study by Zoppi et al (157) the 
within-run IMg CVs range from 0.67% to 3.00% and the day-to-day precision range 
between 3.91% to 5.89%. Hristova et al (71) reported within-run IMg CVs for low, 
medium and high controls of 2.60%, 0.77% and 1.07%, respectively, and the day-to-day 
CVs for low, medium and high of 2.63%, 3.06% and 4.93%, respectively. Filos et al 
(54) reports within-run and day-to-day precision CVs of <3.05 and <6.40%, 
respectively. In all cases, the within-run imprecision was less than the day-to-day 
imprecision.
In this study, the within-run IMg CVs for low, medium and high protein-based control 
solutions are 2.30%, 0.98% and 1.05%, respectively. The day-to-day CVs for low, 
medium and high protein-based solutions are 2.81%, 3.15% and 4.04%, respectively. 
Estimation of analyser precision on human serum samples was important because of 
matrix differences and the heterogeneity of serum samples, compared with protein- 
based control solutions. The CVs obtained using serum samples were equal to or lower 
than those obtained with the protein-based control solutions. The within-run CVs for
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Serum A, B and C were 1.05%, 0.94% and 0.95%, respectively. The day-to-day CVs 
for Serum A, B and C were 2.76%, 2.30% and 2.50%, respectively (Table 2.2).
In conclusion, from the analysis of the protein-based control solutions and serum 
samples, this precision study confirms that the precision of the AVL IMg ISE was 
suitable for the sequential monitoring of serum IMg concentrations in the clinical 
diagnostic setting.
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C h a p t e r  3 -  
E f f e c t  o f  d u r a t io n  a n d
TEMPERATURE OF STORAGE ON 
STABILITY OF IONISED MAGNESIUM IN 
SERUM AND WHOLE BLOOD
3.1 Introduction
For clinical work, and future studies, it is essential that storage variables be investigated 
in samples for IMg analysis. The determination of IMg using ISEs is a potentially 
valuable new tool for studies of magnesium metabolism, yet little is known about the 
stability of IMg in serum and whole blood on storage. Incomplete and controversial 
data exists about the reproducibility of serum and whole blood IMg after storage, with 
only passing reference to the effect of time on the result obtained (65).
Under certain clinical situations, there are advantages to using either serum or whole 
blood. Whole blood samples have the advantage in that under urgent conditions they 
can be analysed immediately without time lost waiting for coagulation and 
centrifugation. However, the storage life of whole blood is generally much shorter than 
serum due to complex factors such as leaching of intracellular ions and proteins, and 
cell lysis, that affect its stability. One important factor to consider is the continued 
metabolism by leukocytes and erythrocytes during storage, which will lower glucose 
levels, increase lactic acid levels and lower the pH. As discussed in Chapter 2, the 
AVL 988-4 analyser mathematically corrects the IMg concentration for pH and ICa 
concentration. For these reasons, it is important to determine how long whole blood 
samples can be stored without affecting EMg stability. On the other hand, the absence 
of cells means that serum samples can generally be stored for longer periods, which 
therefore allows flexibility in time of analysis.
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The aims of this study were to determine the most suitable condition for storage of 
serum and whole blood samples for the subsequent determination of IMg, to determine 
the extent to which these sample types deteriorate over time and to determine if there 
are any differences in IMg concentration, irrespective of whether one samples whole 
blood or serum.
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3.2 Materials and Method
3.2.1 Instrument
Ionised magnesium in serum and whole blood was measured on the AVL 988-4 
analyser, as described in Chapter 2, Section 2.2.1, page 41.
3.2.2 Serum Samples
Venous blood (7.5 mL) was collected from 10 volunteers under anaerobic conditions by 
using the Monovette (Serum Gel) syringe system. A copy of the Consent Form and the 
Collection Protocol are reproduced in Appendix A and B, respectively. The blood was 
allowed to clot for at least 15 minutes at room temperature after collection and 
centrifuged at 3500 rpm for 10 minutes. Serum was separated and analysed in duplicate 
for IMg concentration. The remaining serum from each specimen was divided into 21 
equal aliquots in capped 0.5 mL cups and stored at either -20 °C, 4 °C or room 
temperature.
3.2.3 Whole Blood Samples
Venous blood (4.0 mL) was collected from seven volunteers under anaerobic conditions 
using the specially designed Monovette syringe systems (Sarstedt, Numbrecht, 
Germany). These collection tubes contained ISE-balanced heparin (anti-coagulant). 
The heparin is titrated with calcium, which limits errors in the determination of IMg. 
After collection, the samples were immediately analysed in duplicate for IMg 
concentration. Each sample was then divided into 12 equal aliquots in capped 0.5 mL 
cups and stored at either 4° C or at room temperature.
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3.2.4 Assessment
Samples were analysed after maintenance, daily calibration and quality control 
procedures were performed on the AVL 988-4 analyser, as recommended by the 
manufacturer. For the serum study, an aliquot from each group was brought to room 
temperature, mixed by gentle inversion and analysed on each day for seven days. 
Samples were measured in the Serum mode. For the whole blood study, an aliquot from 
each group was brought to room temperature, mixed by gentle inversion and analysed at 
30-minute intervals for 180 minutes after collection. Samples were measured in the 
Whole Blood mode. For the comparison study between serum and whole blood IMg, 
two venous blood samples were collected as outlined in Sections 3.2.2 (Serum Sample) 
and 3.2.3 (Whole Blood) from 50 volunteers. Samples were analysed within 30 minutes 
of collection in the Serum or Whole Blood mode.
3.2.5 Statistical Analysis
The mean, standard deviation (SD) and standard error of the mean (SEM) were 
calculated for IMg, at each time interval tested, for each sample type and storage 
condition.
For the comparison between serum and whole blood study, statistics were obtained by 
linear regression analysis. As the data were not normally distributed, the Mann­
Whitney Rank Sum Test (two-sample test) was employed for assessment of differences 
in serum and whole blood IMg concentrations. Significant differences between group 
means were inferred for P <0.05.
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3.3 Results
3.3.1 Serum Samples
Figure 3.1 shows the stability of serum IMg concentration during 7 days of storage at 
room temperature, 4 °C or -20 °C. All points are the mean of ten serum samples. 
Initially, the mean serum IMg concentration was 0.53 ± 0.06 mmol/L. The shaded area 
indicates a 4.04% CV, the day-to-day precision (from Chapter 2). After 7 days of 
storage at room temperature, 4 °C and -20 °C, there was a decrease of 3.4%, 2.3% and 
0.95% in serum IMg concentration, respectively. The standard deviation after seven 
days of storage at room temperature, 4 °C and -20 °C was 0.07 mmol/L, 0.06 mmol/L 
and 0.05 mmol/L, respectively.
Figure 3.1
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3.3.2 Whole Blood Samples
Figure 3.2 illustrates the stability of whole blood IMg over 180 minutes when stored at 
room temperature or at 4 °C. All points are the mean of seven whole blood samples. 
Initially, the mean whole blood EMg concentration was 0.54 ± 0.06 mmol/L. 
The shaded area indicates a 4.04% CV, the day-to-day precision. From 0 to 120 
minutes there was a decrease of 1.3% in whole blood IMg concentration, at both storage 
conditions. The standard deviation after 120 minutes of storage at room temperature or 
at 4 °C was 0.06 mmol/L.
Figure 3.2
Mean (+SEM) whole blood IMg concentrations during 3 hours of storage.
4 °C
Room Temp.
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From 0 to 180 minutes, there was a decrease of 10.8% in whole blood IMg 
concentration, stored at room temperature. At 4 °C there was a decrease of 3.0% in 
whole blood IMg concentration. The standard deviation of samples after 180 minutes of 
storage at room temperature or 4 °C was 0.06 mmol/L.
3.3.3 Serum and Whole Blood Sample Comparison
A correlation study was performed on measurements of serum and whole blood IMg 
(Figure 3.3). The slope was 1.001 and the intercept was -0.006 mmol/L. The data had 
a correlation coefficient (r) of 0.983 and standard error of the regression (Sy x) of 0.013. 
Furthermore, the mean values for IMg obtained from serum and whole blood are 
virtually identical, 0.57 ± 0.07 mmol/L and 0.56 ± 0.07 mmol/L, respectively. There is 
no significant (P = 0.674) difference between the IMg concentrations obtained from 
serum or whole blood.
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Figure 3.3
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3.4 D is c u s s io n
The criterion for IMg stability was the day-to-day precision of the ISE. If the precision 
of serum results obtained over the seven-day period remained within the day-to-day 
precision (CV of <4.04%), obtained in Chapter 2, then they were considered the same as 
the initial values. Serum sample stability was acceptable over a seven-day period at all 
temperatures tested. Results for the specimens did not exceed the 4.04% CV limit. 
However, although all storage temperatures were within the acceptable limits, the best 
results obtained were from those samples stored frozen at -20 °C. After seven days at 
-20 °C, these samples had the lowest percentage decrease (0.95%) in IMg concentration 
from initial values.
These finding are consistent to the values obtained by Halpem et al (65). Halpem’s 
group examined 10 sera stored for 10 days, refrigerated at 4 °C and frozen at -15 °C, 
using the AVL 808-4 analyser. On the tenth day, the mean IMg concentration did not 
vary more than 0.40% from the initial value for both storage conditions. Likewise, 
Halpem et al (65) concluded that IMg reproducibility was good at both storage 
temperatures. However, the lower standard deviation (±0.02 mmol/L) obtained from 
the frozen samples was enough to consider freezing as the better storage condition.
Refrigerated whole blood samples were acceptable for analysis up to 180 minutes of 
storage, with mean results not exceeding the 4.04% CV limit. At 180 minutes of 
storage at 4 °C, there was a 3.0% decrease in IMg concentration from initial values. 
By comparison, there was an unacceptable 10.8% decrease in IMg concentration in
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those samples stored at room temperature, with results exceeding the 4.04% CV limit. 
The best results obtained were from those samples stored up to 120 minutes. There was 
a decrease of 1.3% in IMg concentration, from the initial value. Previous studies have 
failed to determine the IMg reproducibility in whole blood after storage. This study has 
shown that whole blood can be stored refrigerated for up to 180 minutes without 
jeopardising sample stability for IMg.
The present study compares for the first time data from serum and whole blood samples 
measured for IMg concentration by the AVL 988-4 IMg ISE. The data shows no 
significant (P = 0.674) difference in IMg concentration between the two sample types. 
The calculated regression coefficient and intercept did not differ significantly from 1 
and 0, respectively (Sy x = 0.013). Similar findings have been reported by Altura et al 
(8, 18) for plasma, serum and whole blood using a NOVA Stat Profile 8 (NOVA 
Biomedical, Waltham, Massachusetts) and KONE (KONE, Espoo, Finland) analysers.
In conclusion, the results of this study confirm that within a clinical laboratory setting 
and for future studies, it is possible to batch appropriately stored samples and process 
them when convenient without affecting sample stability and IMg reproducibility. 
Furthermore, the results in IMg concentration, obtained from either serum or whole 
blood samples, are nearly identical, indicating that, depending upon the urgency for IMg 
determination, either sample type may be used.
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C h a p t e r  4 -  
T h e  m e a s u r e m e n t  o f
SERUM IONISED MAGNESIUM 
FOR THE DETECTION OF 
ACUTE MYOCARDIAL INFARCTION
4.1 In t r o d u c t i o n
After the onset of clinical symptoms in patients with AMI there is a time lag period 
during which enzymes released from the damaged myocardial tissue increase in serum. 
The quantitation of myocardial isoenzymes, for example CK-MB, is used as an aid in 
the diagnosis of myocardial injury (30, 73, 147). Figure 4.1 shows a representative 
serum CK-MB concentration profile following myocardial infarction. A serial rise and 
fall in CK-MB is characteristic of myocardial infarction. CK-MB levels rise 3 to 8 
hours following the onset of chest pain, with peak concentration obtained within 10 to 
24 hours, returning to normal range within 24 to 48 hours (79). However, there are 
several limitations to using measurements of CK-MB. Albeit in small quantities, CK- 
MB is present in other tissue, such as skeletal muscle, and therefore a rise in CK-MB is 
not always indicative of AMI. Skeletal muscle regenerative processes due to injury, for 
example, elevate serum CK-MB proportionally (23, 81, 142). Furthermore, conditions 
such as cardiac surgery for coronary bypass, valve replacement, polymyositis, muscular 
dystrophies, chronic renal failure with dialysis, repair of congenital defects or any cause 
of acute and chronic muscle injury have been reported to cause elevated serum CK-MB 
levels (79). In these cases, however, the CK-MB levels do not exhibit the characteristic 
rise and fall associated with myocardial injury, but care still needs to be taken not to 
confuse these elevated CK-MB levels with genuine cardiac injury. It has been 
suggested that calculating the percentage of CK-MB in relation to total CK can be used 
to determine whether elevations of CK-MB are of skeletal muscle or cardiac origin. 
This strategy suffers from substantial loss of sensitivity if patients have both cardiac and 
skeletal muscle damage (106).
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Figure 4.1
Representative serial serum CK-MB concentration profile following 
myocardial infarction. Time 0 represents the onset of chest pain.
One marker that is currently under investigation and now challenges CK-MB as the 
gold standard for detection of myocardial injury is cardiac troponin-I (cTn-I). Troponin 
is a contractile regulatory protein complex present in striated muscle. Troponin is a 
complex of three proteins, troponin-C (calcium binding component), troponin-I 
(inhibitory component), and troponin-T (tropomyosin binding component), that act 
together to regulate calcium-dependent interactions between myosin and actin, and 
therefore regulate muscle contraction (22). Cardiac troponin-I has been shown to have 
complete (100%) specificity to cardiac muscle (3, 22). Several reports indicate that 
cTn-I concentrations increase above the reference range within 4 to 8 hours following
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chest pain. The cTn-I level peaks at 12 to 48 hours and remains elevated for 7 to 9 days 
following AMI (4, 85). Its high specificity for the myocardium suggests that troponin-I 
may replace CK-MB in any setting where the specificity of CK-MB is in doubt. 
Several reports also indicate that apart from its diagnostic value, the analysis of cTn-I 
has prognostic value in patients with unstable angina and cardiac disease (21, 60, 156). 
For example, Antman et al (21) reports that elevated serum cTn-I concentrations, on 
admission, may predict death by 42 days in unstable angina and improved survival with 
an early invasive strategy.
Although the diagnosis of AMI is straight forward when anginal pain is accompanied by 
typical changes on the ECG, thrombolytic therapy needs to be administered rapidly 
before AMI is confirmed by more time-consuming measurements of cardiac markers 
such as CK-MB (119, 143). However, in approximately 30% of all patients with chest 
pain, the ECG on admission is non-diagnostic (19, 62). A correct diagnosis of 
myocardial cell injury depends entirely on the result of biochemical assays.
Serum TMg concentrations in AMI have been studied on some occasions. While some 
reports could not demonstrate any significant changes in the serum TMg concentration 
after the onset of myocardial infarction, most studies have shown a significant decrease 
(2, 14, 34, 35, 46, 58, 66, 72, 113). However, those studies that had found a significant 
change in the level of serum magnesium failed to determine the value of this test as an 
aid in the diagnosis of AMI. Ionised magnesium may prove to be of clinical value as a
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tool in diagnosing AMI and may be extremely beneficial in the management of these 
patients.
The present investigation was performed to establish serum IMg, TMg and CK-MB 
levels in AMI and non-AMI patients. The objective was also to compare serum IMg to 
one of the current cardiac markers, CK-MB, and from this to determine if IMg may be 
used as a diagnostic tool for myocardial infarction.
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4.2 Materials and Methods
4.2.1 Analytical Methods
4.2.1.1 Ionised magnesium determination
Ionised magnesium in serum was measured on the AVL 988-4 analyser, as described in 
Chapter 2, Section 2.2.1, page 41.
4.2.1.2 CK-MB determination
CK-MB in serum was measured on the ACS: 180, Automated Chemiluminescence 
System (Ciba Coming Diagnostics Corp. Medfield, Massachusetts). The Ciba Coming 
CK-MB II assay is a two-site chemiluminometric (sandwich) assay, which uses 
constant amounts of two antibodies. The first antibody (‘Lite’ Reagent) is a 
monoclonal mouse anti-CK-MB antibody labelled with acridinium ester. The second 
antibody (Solid Phase) is a monoclonal mouse anti-CK-BB antibody covalently 
coupled to paramagnetic particles. A direct relationship exists between the CK-MB in a 
sample and the relative light units detected by the ACS: 180 system. The assay is 
unaffected by increased levels of the other CK isoenzymes. A 100 pL sample is 
required for analyses and the results are available approximately 15 minutes after 
sample introduction. The ACS CK-MB II assay measures CK-MB concentrations 
ranging from 0.65 pg/L to 500 pg/L, the normal levels are typically <5 pg/L.
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4.2.1.3 Total magnesium determination
Total magnesium in serum was measured on the Vitros 700 Analyser (Johnson & 
Johnson Clinical Diagnostics, Inc., Rochester, New York). The Vitros magnesium 
Slides (dry chemistry) quantitate magnesium concentration in serum, plasma and urine, 
colorimetrically. A 10 jiL drop of sample is required to react with the formazan dye 
derivative on the Vitros magnesium Slide and the results are available after 
approximately 5 minutes. The high magnesium affinity of the dye dissociates 
magnesium from binding proteins and the resulting magnesium-dye complex causes a 
shift in the dye absorption maximum from 540 nm to 630 nm, the reflection density of 
the coloured complex is measured spectrophotometrically. The amount of dye complex 
formed is proportional to the magnesium concentration. The Vitros magnesium assay 
measures TMg concentrations ranging from 0.08 -  4.11 mmol/L; in our laboratory the 
normal reference range is 0.71 -  0.90 mmol/L.
4.2.2 Sample Collection
An initial sample from each patient was collected in the Emergency Department after 
AMI was suspected and/or diagnosed. Subsequent samples were collected during the 
patients’ stay in Coronary Care Unit (CCU) and/or Sub-Acute Coronary Care Unit 
(SACCU). Blood samples were obtained at least every 6 to 8 hours for up to 66 hours in 
the AMI group and up to 36 hours in the non-AMI group. Venous blood (7.5 mL) was 
collected under anaerobic conditions using the Monovette (Serum Gel) syringe system. A 
copy of the Collection Protocol is reproduced in Appendix B. Blood was allowed to clot 
for at least 15 minutes at room temperature after collection and centrifuged at 3500 rpm
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for 10 minutes. Samples for TMg and CK-MB were stored at 4 °C until analysis. 
Samples were assayed within 8 hours after collection. For IMg, serum samples were 
stored at —20 °C for up to 3 days before batch analysis.
4.2.3 Statistical Analysis
The mean, standard deviation (SD) and standard error of the mean (SEM) were 
calculated for IMg, TMg and CK-MB at each time interval monitored, for both the AMI 
and non-AMI groups.
The selection of the appropriate statistical tests used was dependent on a number of 
assumptions about the condition of that data. It was determined that the data did not 
follow a normal distribution and the statistical analysis would have to employ 
nonparametric tests. The Mann-Whitney Rank Sum Test (two-sample test) was 
employed for assessment of differences in either IMg or TMg levels between the AMI 
and non-AMI groups. Significant differences between group means were inferred at 
P <0.05.
The Kruskal-Wallis One Way Analysis of Variance on Ranks was employed for 
assessment of differences (intergroup) in both IMg and TMg concentrations in the AMI 
and non-AMI groups, at each 6 hour time interval monitored. Significant differences 
between group means were inferred at P <0.05.
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One hundred and sixty-two patients who were admitted consecutively to the CCU and 
SACCU, Illawarra Regional Hospital (Wollongong, NSW, Australia), with a provisional 
diagnosis of AMI, were studied. The 106 male and 56 female patients, ranging in age 
from 25 to 90 years, gave written informed consent to participate in the study after a 
thorough explanation of the study protocol. A copy of the Consent Form is reproduced in 
Appendix A. The Ethics Committee of the University of Wollongong (Wollongong, 
NSW, Australia) approved this investigation.
Some of the clinical characteristics of the patients studied are described in Table 4.1. 
Retrospective investigation of medical records revealed that 50 male and 22 female 
patients, ranging in age from 39 to 90 years (mean age 68.4 ± SD 12.9 years) had AMI. 
Hereafter, these patients will be referred to as the AMI group. The diagnosis of AMI was 
made by the clinicians responsible for the patient based on the criteria established by the 
World Health Organization (155). These criteria include patient history, the presence of 
typical and atypical chest pain, unequivocal changes in the ECG and increased 
concentrations of CK-MB on serial blood collections. The remaining 56 males and 34 
females, ranging in age from 25 to 88 years (mean age 68.1 ± SD 13.0 years), suffered 
from chest pain in which a diagnosis of AMI was ruled out. Hereafter, these patients will 
be referred to as the non-AMI group.
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Table 4.1
Clinical characteristics of patients studied.
AMI Group Non-AMI Group
n 72 90





Previous AMI 10 11
Angina pectoris 20 28
CHF/IHD 18 37
None 24 14
CHF -  Congestive Heart Failure; IHD = Ischaemic Heart Disease.
Table 4.2 shows the IMg, TMg and CK-MB data for all the patients studied. For AMI 
patients, the data are further grouped according to an approximate time after the onset 
after the chest pain. Fifty-seven of the AMI group presented sufficiently early that 
values of CK-MB were either normal (n = 37) or were beginning to increase (n = 20), 
permitting more complete data acquisition on the time course of changes in CK-MB 
and IMg. All AMI patients followed the typical profile in serial CK-MB measurements 
as described in Section 4.1. Maximum CK-MB values were obtained approximately 
1 8 - 2 4  hours after the onset of chest pain. Within this time interval, the mean ± S.D 
peak CK-MB value was 97.4 ± 101 jug/L (range 6.7 -  >386 |Lig/L).
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Table 4.2








IMg (mmol/L) TMg (mmol/L) CK-MB (pg/L)
Mean SD Range Mean SD Range Mean SD Range
0-6 20 0.512 0.043 0.45-0.60 0.759 0.062 0.65-0.86 6.7 12.7 0.5-54.8
6-12 44 0.517 0.057 0.43-0.74 0.777 0.082 0.58-0.91 20.6 40.1 0.3-252.5
12-18 18 0.514 0.046 0.44-0.59 0.773 0.089 0.60-0.86 37.6 42.9 0.2-161.6
18-24 72 0.476 0.051 0.38-0.60 0.762 0.088 0.58-0.91 97.4 101 6.7-386
24-30 20 0.479 0.058 0.39-0.58 0.761 0.088 0.64-0.94 75.8 86.3 12.5-301
30-36 43 0.503 0.049 0.39-0.60 0.762 0.081 0.60-0.92 57.2 73.1 3.9-319.9
36-42 31 0.507 0.047 0.39-0.60 0.771 0.082 0.64-0.93 42.3 54.6 2.8-210.5
42-48 23 0.510 0.055 0.40-0.66 0.775 0.039 0.73-0.85 34.7 30.2 4.7-78.0
48-54 9 0.515 0.022 0.47-0.54 0.753 0.040 0.70-0.81 18.4 16.4 5.5-46.0
54-60 12 0.514 0.047 0.45-0.59 0.760 0.075 0.66-0.87 10.2 10.4 2.9-30.6
60-66 11 0.519 0.045 0.42-0.57 0.754 0.080 0.54-0.87 6.4 4.4 1.1-13.2
Non-AMI 90 0.520 0.065 0.30-0.76 0.792 0.085 0.53-1.07 1.44 0.9 0.2-4.5
4.3.2 Serum CK-MB concentrations of non-AMI and AMI groups.
After the onset of chest pain, CK-MB concentrations were monitored to observe any 
changes over time in both the non-AMI and AMI groups. It was important to observe the 
timing and typical pattern of rise and fall (as described in Section 4.1) of CK-MB 
concentrations in the AMI group studied, and to compare our observations with the 
established representations of CK-MB changes associated with AMI.
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Figure 4.2 shows the mean concentrations of serum CK-MB in the non-AMI group over 
time, with error bars indicating the SEM. The non-AMI group was monitored for up to 
36 hours after the onset of chest pain. Of the 90 patients diagnosed as not having 
myocardial infarction, none had a value of CK-MB above the reference range (<5 pg/L) 
throughout the monitoring period. The overall mean ± SD in CK-MB concentration of 
the non-AMI group was 1.44 ± 0.91 pg/L. No significant difference (P = 0.979) in 
CK-MB concentration was observed between each 6 hour time interval monitored.
Figure 4.2
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Figure 4.3 shows the mean concentrations of serum CK-MB in the AMI group over time, 
with error bars indicating the SEM. All patients diagnosed with AMI had at least one 
value of CK-MB above the reference range (>5 jig/L) during the monitoring period. 
Of these 72 patients, 12 had only modest increases in peak CK-MB (all <25 jag/L), 55 
had high CK-MB values (between 25 -300 jag/L), and the remaining 5 patients had very 
high CK-MB values (>300 Jig/L).
Figure 4.3
Mean serum CK-MB concentrations of AMI patients.
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The data shows that CK-MB levels began to rise during the critical first 6 hours after the 
onset of chest pain. Peak CK-MB concentrations (i.e. 97.4 ± 101 Jug/L) were observed by 
1 8 -2 4  hours. This was a 93.1% increase in CK-MB levels compared to initial values. 
The observed pattern in CK—MB levels, after the onset of chest pain, agreed with 
established CK-MB observations following AMI (30, 73, 147).
4.3.3 Serum TMg and CK-MB concentrations of non-AMI and AMI 
groups.
A comparison was made between CK-MB and TMg levels for both the non-AMI and 
AMI groups. Figure 4.4 shows the mean concentrations of serum TMg and CK-MB in 
the non-AMI group over time, with error bars indicating the SEM. The overall TMg 
concentration of the non-AMI group was 0.79 ± 0.09 mmol/L. Like CK-MB, TMg 
concentrations did not significantly differ (P = 0.597) between each 6 hour time interval 
monitored.
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Figure 4.4
Mean serum concentrations of TMg and CK-MB of non-AMI patients.
TMg
(mmol/L)
Time after the onset of chest pain 
(Hours)
Figure 4.5 shows the mean concentrations of serum TMg and CK-MB in patients with 
AMI over time, with error bars indicating the SEM. The overall TMg concentration of 
the AMI group was 0.77 ± 0.08 mmol/L. Total magnesium concentrations remained 
within the normal reference range (0.71 -  0.90 mmol/L) at each 6 hour time interval 
monitored. Comparing the TMg concentrations of the AMI group at each 6 hour time 
interval revealed no significant (P = 0.996) changes over the 66 hours of study. These 
findings are in agreement with those authors (45, 82, 100, 152) reporting normal TMg 
concentrations in patients with AMI and disagree with those authors (2, 14, 34, 35, 46, 58, 
66, 72, 114) that report a decrease in TMg concentration in AMI patients.
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4.3.4 Serum IMg and TMg concentrations of non-AMI and AMI 
groups.
A comparison was made between serum CK-MB and IMg levels for non-AMI and AMI 
groups. Figure 4.6 compares the mean concentrations of serum IMg and TMg in the 
non-AMI group over time, with error bars indicating the SEM. The overall IMg 
concentration of the non-AMI group was 0.52 ± 0.06 mmol/L. Like TMg, IMg 
concentrations remained within the normal reference range (0.50 -  0.65 mmol/L),
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throughout the 36 hours of study. No significant difference (P = 0.276) in IMg 
concentration was observed between each 6 hour time interval monitored.
Figure 4.6
Mean serum concentrations of IMg and TMg of non-AMI patients.
TM g
(m m ol/L)
Time after the onset o f  chest pain 
(Hours)
Figure 4.7 shows the mean concentrations of serum IMg and TMg of patients with AMI 
over time, with error bars indicating the SEM. From 0 to 18 hours after the onset of 
chest pain, the IMg concentrations in the AMI group was within the normal reference 
range (0.50 -  0.65 mmol/L). However, at the 18 -  24 and 24 -  30 hour time intervals, 
IMg concentrations decreased to 0.48 ± 0.05 mmol/L (range 0.38 -  0.60 mmol/L) and
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0.48 ± 0.06 mmol/L (range 0.39 -  0.58), respectively. At the 18 -24  hour time interval, 
this constituted a 7.0% decrease in serum IMg in the AMI group. The decrease in IMg 
levels in the AMI group was significant (P <0.001) within the 66 hours of study. 
Ionised magnesium levels then returned to normal levels by 30 -  42 hours. The overall 
IMg concentration in the AMI group was also found to be 0.50 ± 0.05 mmol/L, which is 
3.8% lower compared to the non-AMI group. Altogether the AMI group had 
significantly lower IMg and TMg concentrations (P <0.001 and P  = 0.004, respectively) 
compared to the non-AMI group.
Figure 4.7
Mean serum concentrations of IMg and TMg of AMI patients.
TM g
(mmol/L)
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4.3.5 Serum IMg and CK-MB concentrations of non-AMI and AMI
groups.
Figure 4.8 shows the serum IMg and CK-MB concentrations of non-AMI patients over 
time, with error bars indicating the SEM. Throughout the 36 hours of study both 
analytes show little fluctuation and both remain within normal reference range.
Figure 4.8
Mean serum concentrations of IMg and CK-MB of non-AMI patients.
IMg
(mmol/L)
Time after the onset of chest pain 
(Hours)
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Figure 4.9 shows the mean serum IMg and CK-MB concentrations of AMI patients 
over time, with error bars indicating the SEM. Following the onset of chest pain IMg 
and CK-MB levels in AMI patients showed an inverse relationship. Unlike CK-MB 
levels which gradually increase in serum (within 3 - 8  hours) to peak at 18 hours, IMg 
levels remain constant for 12 -  18 hours before falling rapidly. The maximum change 
in IMg occurs within a short period of about 6 hours. As CK-MB returns to base line 
levels in the next 48 hours, IMg levels also return to normal levels but more quickly, 
within 3 0 -4 2  hours.
Figure 4.9
Mean serum concentrations of IMg and CK-MB of AMI patients.
Time after the onset o f chest pain 
(Hours)
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Figure 4.10 illustrates the inverse relationship between IMg and CK-MB, in AMI 
patients. Separating patients according to their CK-MB levels clearly identified a 
decrease in IMg with CK-MB increases. AMI patients (n = 18) with only modest 
increases in peak CK-MB (<25 pg/L), had mean IMg concentrations of 0.501 ± 0.063 
mmol/L. AMI patients (n = 32) with CK-MB ranging from 25 -  100 pg/L, had mean 
IMg concentrations of 0.474 ± 0.047 mmol/L. AMI patients (n = 13) with CK-MB 
ranging from 100 -  200 pg/L, had mean IMg concentrations of 0.469 ± 0.043 mmol/L. 
Those AMI patients (n = 9) with CK-MB ranging from 200 -  >386 pg/L, had mean 
IMg concentrations of 0.443 ± 0.024 mmol/L.
Figure 4.10
Proportional decrease in IMg to CK-MB increase.
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These findings led to the investigation for a relationship between CK-MB and IMg 
concentrations. Figure 4.11 shows the scatter graph of the square root of CK-MB and 
IMg concentrations of non-AMI patients. The square root transformation of CK-MB 
concentrations was selected to achieve close approximations to normality, since the data 
obtained was not normally distributed. The correlation coefficient was 0.066, which is 
not statistically significant (P -  0.27). The linear equation was IMg = 0.522 -  0.011 x 
(CK-MB). The non-AMI group shows a spread of points both horizontally (CK-MB) 
and vertically (IMg) demonstrating poor correlation. The trend line indicates a slight 
decreasing trend for IMg with increasing CK-MB. The lack of correlation indicated 
that there is no relationship between serum IMg and CK-MB concentrations in 
non-AMI patients.
Figure 4.11
Correlation between serum CK-MB and IMg concentrations of non-AMI patients.
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Figure 4.12 shows the scatter graph of the square root of CK-MB and IMg 
concentrations of AMI patients. By comparison, the trend line for AMI patients 
indicates a decreasing trend for IMg with increasing CK-MB. The correlation 
coefficient was 0.383, which is statistically significant (P = 0.002). The linear equation 
was IMg = 0.509 -  0.004 x (CK-MB). The AMI group shows tight horizontal 
clustering (CK-MB) with a spread of points vertically (IMg), resulting in a significant 
correlation.
Figure 4.12
Correlation between serum CK-MB and IMg concentrations of AMI patients.
IMg
(mmol/L)
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4.3.6 Predictive value of IMg in the diagnosis of AMI.
It was apparent that the AMI group of patients could be distinguished from the non­
AMI group on the differences in IMg. The 1 8 - 2 4  hour time interval, following the 
onset of chest pain (Figure 4.9), was the period exhibiting the greatest statistical 
difference in the mean IMg concentration between the AMI and non-AMI groups. 
A cut-off point was selected rather than a reference range for the normal population as 
overall IMg concentrations varied from patient to patient. For example, AMI patients 
had decreases in IMg concentrations (at the 18 -  24 hour time interval) that were still 
within the normal reference range. In addition, low IMg concentrations were also 
detected in patients without AMI. From the data, the best cut-off point at the 18 -  24 
hour time interval was determined to be <0.47 mmol/L. This value allowed the highest 
sensitivity, specificity and overall efficiency of IMg for predicting AMI.
The usefulness of applying this criterion to the data can be determined by calculating 
the diagnostic sensitivity, specificity, predictive value and efficiency of the selection 
rules. The sensitivity of the test is a measure of the frequency of a positive test when 
AMI is present. Specificity is a measure of the frequency of a negative test when there 
is no AMI present. The predictive value of the test is the frequency of AMI occurring in 
those patients who have decreased IMg concentrations. The efficiency of a test indicates 
the percentage of patients who have been correctly classified by the test result as having 
or not having AMI (139). Table 4.3 shows the predictive value of IMg for diagnosing 
AMI.
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Table 4.3









AMI + 43 28 71
AMI“ 26 65 91
Total 69 93 162
Sensitivity == 61% Predictive value = 62%
Specificity == 71% Efficiency of test = 67%
Patients in which a diagnosis of AMI was established using traditional parameters. 
Patients in which a diagnosis of AMI was excluded using traditional parameters.
In this application, 62% of the patients with low IMg had AMI. Overall, 67% of 
patients were correctly classified as AMI or non-AMI by using IMg. The sensitivity 
and specificity values indicated that IMg measurement correctly classified patients 
within 61% of cases, and correctly eliminated AMI in normal individuals in 71% of 
cases. The current data indicate that the clinical sensitivity, specificity and the 
predictive value of using serum IMg for the diagnosis of AMI are insufficient for 
effective clinical diagnosis.
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4.4 Discussion
Biochemical markers, in particular CK-MB, have become the ‘gold standard’ for 
diagnosis of AMI. For the diagnosis of AMI, the ideal biochemical test must have a 
good clinical performance as indicated by the diagnostic sensitivity and specificity, 
showing discrete separation between AMI and non-AMI patients. This study compares 
for the first time the sequential quantitation of serum IMg and CK-MB for the detection 
of myocardial cell death and damage due to AMI.
The results obtained in this study show that serum IMg levels in AMI patients drop 
significantly (P <0.001) by 7.0% compared to initial values. This finding agrees with 
those of Dyckner (46), Flink et al (58) and Rector et al (113) who reported a decrease of 
serum magnesium of 4.7%, 6.2% and 11.2%, respectively. The non-AMI group had no 
significant (P -  0.276) change in their IMg levels over the time monitored. Serum IMg 
follows a characteristic fall and rise in those patients with AMI, which is inversely 
related to the serum CK-MB over the same period. The statistically significant 
(P = 0.002) correlation (r = 0383) between CK-MB and IMg confirmed this relationship.
By using a cut-off value of <0.47 mmol/L, the predictive value (62%) of IMg for AMI 
was low, with a sensitivity of 61% and a specificity of 71%, with an overall efficiency 
of testing of 67%. These values are low when compared to CK-MB (sensitivity 91.5%, 
specificity 97.4%). Nevertheless, the predictive usefulness of IMg may increase when 
used in conjunction with other more conventional parameters such as the ECG.
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This study found no significant change in serum TMg concentrations in both AMI 
(P 0.996) and non-AMI (P -  §597) patients within the monitoring period. This finding 
agrees with other reports (45, 82, 100, 151) that found no significant change in serum 
TMg concentrations in patients with AMI. Serum TMg concentrations remained 
constant with little fluctuation throughout the time monitored. Overall, the serum TMg 
concentrations of both groups remained within the normal reference range.
Although different studies (2, 14, 34, 35, 46, 58, 66, 72, 113) report that a decrease in 
serum magnesium occurs in acute ischaemia, this is not a universal finding. 
Controversy exists because other studies report normal (45, 82, 100, 151) and even 
raised (41, 48) serum magnesium concentrations. From the data in this study, it seems 
likely that hypomagnesaemia associated with AMI may only be transient, and serum 
IMg levels may fluctuate with ischaemic events. This suggests that the time intervals 
used for obtaining blood samples from AMI patients in previous studies were too broad 
to measure such rapid fluctuations. The time lag between the onset of myocardial 
infarction and determination of magnesium varies from several hours after admission to 
the hospital to two weeks after infarction. Dyckner (46) observed a decrease in 
magnesium levels in samples collected less than 24 hours after the onset of AMI. Ebel 
et al (48), on the other hand, reports of studies that have obtained normal magnesium 
concentrations 24 to 72 hours after the acute event. Therefore, if the samples were 
taken late in the course of the disease, the magnesium levels may well have returned to 
normal. Another reason why the role of magnesium in myocardial infarction has been
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inadequately defined is that, with few exceptions, the majority of studies to date have 
focused on TMg and not the biologically active fraction, IMg.
There are several theories to explain the changes in serum magnesium concentration 
after myocardial infarction. One explanation is that, several hours after myocardial 
infarction, the IMg released from infarcted areas of the heart lead to a transient increase 
in serum magnesium levels. Experimentally induced myocardial infarction has shown 
that there is an immediate efflux of magnesium from the ischaemic area into the blood 
from the coronary sinus (48, 108). The magnesium content of the necrotic area drops 
by up to 30% during the first hour. However, as pre-infarction magnesium levels are 
usually not known, this initial rapid rise may be overlooked. Subsequently, less than 24 
hours after myocardial infarction, magnesium levels may decrease due to an increased 
renal loss following the secretion of catecholamines, i.e. adrenaline and noradrenaline 
(149).
Other explanations for the post-infarction decrease in serum magnesium are also 
possible. Flink et al (58) investigated the correlation between decreased magnesium 
levels and an increase in fatty acids following AMI. The rise in free fatty acid levels is 
due to an increase in lipolysis induced by a rise in increased catecholamine secretion as 
a result of the infarct. Since free fatty acids bind with magnesium, it has been assumed 
that the overall serum magnesium levels are reduced.
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Another explanation for the lowering of serum magnesium during increased lipolysis is 
the increased binding of magnesium by free fatty acids within adipocytes (i.e. cells that 
store fat). Adrenaline has been shown to increase magnesium uptake by these cells. 
Ebel et al (48) reports that this small increase in magnesium intake by adipose tissue is 
sufficient to produce the small decreases (4.7% to 11.2%) observed in magnesium 
levels. Therefore, due to different amounts of adipose tissue and catecholamine 
secretion among individuals, the decrease in serum magnesium might differ from 
patient to patient.
In conclusion, the data presented here show that the measurement of serum IMg levels 
is a better indicator of magnesium status, than serum TMg, in patients with AMI. 
Although AMI patients were found to have a characteristic pattern of fall and rise in 
their serum IMg levels, it was determined that the measurement of serum IMg alone is 
not diagnostic for AMI. From the theories outlined above, the decrease in serum 
magnesium levels in AMI is uncertain and may be a secondary phenomenon. 
Nevertheless, serum IMg levels may be used as an additional clinical tool for 
assessment of myocardial injury, along side CK-MB and ECG recordings.
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C h a p t e r  5 -  
S u m m a r y  a n d
CLINICAL IMPLICATIONS
Chapter 2 of this thesis aimed to verify previous precision studies on the AVL 988-4 
IMg ISE. Previous studies based their estimates of instrument precision on the results 
from protein-based solutions. These may not reflect the true performance of the IMg 
ISE with clinical samples. The inclusion of serum samples to determine analyser 
precision was one improvement in this study. The within-run and day-to-day precision 
were determined to be <2.30% and <2.81%, respectively. From this study it was 
concluded that the AVL IMg ISE was suitable for patient monitoring.
Chapter 3 was aimed at determining the effect of duration and temperature of storage on 
the stability of IMg in clinical samples. A comparison was also made between serum 
and whole blood to determine if both sample types were acceptable for IMg analysis. 
Both sample types have their advantages under certain clinical situations. From this 
study it was concluded that whole blood samples were only acceptable for IMg analysis, 
if stored for less than 3 hours at 4 °C. Serum samples were acceptable for IMg analysis 
up to 7 days of storage at -20 °C. Furthermore, it was determined that there is no 
significant (P = 0.674) difference in IMg concentration by using either whole blood or 
serum samples. Under urgent conditions the use of whole blood samples would result 
in much quicker turnaround times. On the other hand, serum has its advantages in that 
it can be stored for longer periods for batch analysis.
Following on from the results of Chapters 2 and 3 it was possible to reliably and 
confidently determine and monitor serum IMg levels. The final objective of this study 
was to determine if IMg concentrations in the AMI group differed from the non-AMI 
group. It should be noted that a study of this type, aimed at monitoring the serum levels
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of EMg and CK-MB in non-AMI and AMI patients, has not been previously done. 
Altogether, serum CK-MB, TMg and IMg concentrations of AMI patients were 
monitored for up to 66 hours after the onset of chest pain. Identical measurements were 
made in non-AMI patients. The AMI group elicited the characteristic pattern of rise and 
fall in CK-MB, whereas non-AMI patients showed no change. Over the same period, 
TMg concentrations remained constant in both the non-AMI and AMI groups, with no 
significant (P = 0.996) changes observed in the AMI group throughout the 66 hours of 
study. On the other hand, IMg concentrations decreased significantly (P <0.001) by 
7.0% in the AMI group, at the 18 -  24 hour time interval. No change in IMg 
concentration was detected in the non-AMI patients over the same period.
These findings led to the investigation for a relationship between CK-MB and IMg 
levels. The correlation (r=0383) between CK-MB and IMg was statistically significant 
(P -  0.002), though too low to be of clinical use on its own. The predictive value (62%) 
of measuring IMg in patients with AMI was also low (sensitivity 61% and specificity 
71%), with an overall efficiency of testing of 67%, but did not preclude its use as a 
diagnostic test in assessing patients with AMI.
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Clinical implications
The diagnosis of massive AMI is generally based on clinical symptoms and ECG 
recordings. In these patients biochemical assays generally serve to confirm this 
diagnosis (77, 94, 97, 140). Only a minority of patients with chest pain, however, has 
clear evidence for AMI on ECG recordings. In the vast majority, the ECG is normal or 
reveals non-specific changes of the ST segment or T wave only. The exclusion of acute 
myocardial cell damage in this large group of patients depends entirely on biochemical 
tests such as CK-MB.
Since magnesium has been reported by numerous authors to decrease in patients with 
AMI, to facilitate the biochemical detection for acute myocardial cell necrosis, this 
study attempted to determine if IMg could be used as a diagnostic tool for the detection 
of myocardial infarction. Measurement of IMg, rather than TMg, gave a better 
indication of magnesium status, especially in circumstances where magnesium 
supplements need to be administered. One major advantage of determining IMg in 
patients with a very high probability of AMI is the cost effectiveness, convenience and 
ease of testing. It allows an almost instantaneous analysis of clinical findings, 
biochemical test results and ECG recordings at the patient’s bedside.
In conclusion, the results obtained from this study show that IMg alone may not provide 
a definitive diagnosis of myocardial damage. Measurement of IMg concentrations 
along with other parameters, such as ECG recordings, may improve the predictive value 
of IMg for the diagnosis of AMI.
Chapter 5 -  Summary and  clinical implications Page 91
A p p e n d i x  A  -  
C o n s e n t  f o r m
I L L A W A R R A
PA T H C E N T R E
A Facility of the lllawarra Area Health Service
lllawarra Regional Hospital EXT:
Wollongong Campus YOUR REF:
P.O.Box 1798 OUR REF:
Wollongong NSW 2500
Telephone: (042) 29 8233 
Facsimile: (042) 20 1514
Measurement of ionised magnesium in patients with
CARDIOVASCULAR DISEASE
The Biochemistry Department of the lllawarra Pathcentre in conjunction with Dr Dwain 
Owensby of the Cardiology Department are assessing ionised magnesium levels in patients with 
cardiovascular disease. Magnesium deficiency has been implicated as a causative agent in 
atherogenesis and cardiovascular disease. This research may help in the understanding of the 
pathogenesis of ischaemic heart disease and cardiovascular events.
We are asking for patients who attend the Coronary Care Unit and the Accident and Emergency 
Department of the lllawarra Regional Hospital, Wollongong Campus to have blood collected on 
admission to the Unit. Healthy aged and sex matched pairs of volunteers will also have blood 
collected for ionised whole blood magnesium level.
If you agree to participate in this study, your results will be reported as data only and you will 
not be identified in any way.
If you have queries regarding any aspect of this research project, please contact Dr Owensby 
Director of Cardiology at the lllawarra Regional Hospital on (042) 201 279 or Ms Karen 
McRae, Research Office, Administration, University of Wollongong NSW 2500. You have the 
right to withdraw from this study at any time without prejudice.
CONSENT FORM
The aims of this project is to monitor magnesium levels in normal patients and patients admitted 
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A p p e n d i x  B  -  
C o l l e c t i o n  p r o t o c o l
C o l l e c t i o n  P r o t o c o l
Before collecting blood ensure a consent form has been completed and signed.
COLLECTING PROCEDURE: (Using supplied Sarstedt Monovette syringe system).
1. Replace the orange cap of a sterile Monovette syringe system with the supplied 
needle adaptor (Do not discard orange cap).
2. Secure needle by twisting clockwise.
3. Puncture vein and withdraw plunger slowly until sufficient blood (approx. 2 mL) is 
collected. Wait until blood flow stops.
4. Remove Monovette from the needle by twisting anticlockwise. (Needle remains in 
vein) and complete blood collection by withdrawing needle from vein.
5. Cap Monovette syringe by securing the original orange cap. Lock piston into 
Monovette base and break off plunger.
6. Mix sample thoroughly.





- Time and Date of collection
8. The sample now needs to be taken to the Biochemistry Department as soon as 
possible for immediate analysis. During transit, keep the sample at room 
temperature. Do not store on ice.
Note: Please do not transfer blood from another type of tube to the Monovette 
syringe.
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